This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Dec 1;4(12):1789-1790.

doi: 10.1001/jamaoncol.2018.5067.

Moving Precision Oncology Forward Amid Myths and Misconceptions

Balkees Abderrahman¹, V Craig Jordan¹

Affiliations

PMID: 30419081
DOI: 10.1001/jamaoncol.2018.5067

Comment

Moving Precision Oncology Forward Amid Myths and Misconceptions

Balkees Abderrahman et al. JAMA Oncol. 2018.

. 2018 Dec 1;4(12):1789-1790.

doi: 10.1001/jamaoncol.2018.5067.

Authors

Balkees Abderrahman¹, V Craig Jordan¹

Affiliation

¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.

PMID: 30419081
DOI: 10.1001/jamaoncol.2018.5067

No abstract available

PubMed Disclaimer

Comment in

Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply.
Marquart J, Chen EY, Prasad V. Marquart J, et al. JAMA Oncol. 2018 Dec 1;4(12):1790. doi: 10.1001/jamaoncol.2018.5111. JAMA Oncol. 2018. PMID: 30419080 No abstract available.

Comment on

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J, Chen EY, Prasad V. Marquart J, et al. JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660. JAMA Oncol. 2018. PMID: 29710180 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems